16/02/2026
π Expanding Access to Advanced CFTR Modulator Therapies
At Ancanex, we collaborate with trusted global distributors to support access to advanced combination CFTR modulator therapies used in the management of cystic fibrosis.
These therapies may be available in different strength configurations suitable for both pediatric and adult patient populations, based on physician guidance and clinical requirements.
Active components in such combination therapies typically include:
β’ Elexacaftor
β’ Tezacaftor
β’ Ivacaftor
They are designed to improve CFTR protein function and support better clinical outcomes in eligible cystic fibrosis patients.
π€ Our Role in Global Supply
Through our international sourcing and distribution network, Ancanex can assist partners with:
β’ Reliable sourcing via verified distributors
β’ Support for pediatric & adult strength requirements
β’ Documentation and regulatory-compliant supply pathways
β’ Cold-chain coordination and global logistics solutions
β’ Access to both branded and equivalent specialty treatments
π Ancanex Vision β βAnti Cancer Exportβ (AnCanEx)
While oncology access is central to our mission, we also extend our support to rare disease therapies where global access remains limited.
Our priority is always the same: helping patients reach quality treatments through responsible and compliant supply channels.
We thank our partners and distributors worldwide who share the same goal β improving access to life-changing therapies.
π© Distributors, hospitals, and procurement teams seeking reliable sourcing for cystic fibrosis and other specialty therapies are welcome to connect with us.
